Bladder Cancer Clinical Trials in Nanjing, Jiangsu
11 recruitingNanjing, Jiangsu, China
Showing 1–11 of 11 trials
Recruiting
Phase 2
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled15 locationsNCT07283835
Recruiting
Phase 2
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Bladder CancerNeuroendocrine Carcinoma of the Bladder
RenJi Hospital22 enrolled5 locationsNCT06091124
Recruiting
Phase 1Phase 2
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Suzhou Forlong Biotechnology Co., Ltd80 enrolled12 locationsNCT07122414
Recruiting
Not Applicable
Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05123625
Recruiting
Phase 4
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
SurgeryBladder CancerCancer Recurrence+2 more
Peking University First Hospital1,128 enrolled6 locationsNCT04532606
Recruiting
Not Applicable
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT07036731
Recruiting
Not Applicable
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
Bladder CancerNMIBC
The First Affiliated Hospital with Nanjing Medical University60 enrolled1 locationNCT06735287
Recruiting
Phase 1
Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School30 enrolled1 locationNCT06551233
Recruiting
Phase 1Phase 2
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.24 enrolled6 locationsNCT06378242
Recruiting
Not Applicable
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT06287541
Recruiting
Not Applicable
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT04588168